Top Ten most popular articles on Pharmafile.com this week

pharmafile | September 1, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Trump, drugs, health, life sciences, medicine, pharma, pharmaceutical, top ten 

This week saw the news of a breakthrough in bispecific antibody production and Merck KGaA finally secured approval for its multiple sclerosis drug after seven years.

Also big news was the release of a government commissioned sector report authored by Sir John Bell, Professor of medicine at the University of Oxford, which sets out how life sciences can form a core part of the UK economy as the UK’s divorce from the EU nears.

But unsurprisingly, the most popular article this week was the news that Novartis received FDA approval for its “historic” CAR T treatment for acute lymphoblastic leukaemia in children.

Check out the week’s ten most popular articles on Pharmafile.com now!

10. New research reports first-ever response of central nervous tumour to CAR T therapy

Researchers at a General Hospital in Massachusetts has reported what they claim is the first response of a nervous system tumour to chimeric antigen receptor T-cell (CAR T) cancer therapy.

9. Seven years later, EC gives approval for Merck KGaA’s MS drug

The seven-year-long road to recovery for Mavenclad has finally been achieved, as it received the nod from the European Commission to treat patients with highly active relapsing multiple sclerosis.

8. Roche receives FDA Priority Review for drug with potted history

Roche, alongside its subsidiary, Genentech, announced that it has received Priority Review for its haemophilia A drug, emicizumab, and that the agency has accepted its BLA.

7. Immunotherapy firm develops breakthrough method for robust bispecific antibody production

A team of researchers have developed an approach to efficiently manufacture bispecific antibodies which are able to bind to two separate target molecules simultaneously.

6. FDA approves first treatment for the ‘silent killer’

The FDA has announced that it has granted an accelerated approval for the use of benznidazole in children between the ages of 2 and 12 years old with Chagas disease.

5. AstraZeneca invests “tens of millions” into Cheshire, UK manufacturing site

AstraZeneca has announced plans to invest a multi-million sum into its £150 million facility in Macclesfield, Chesire, UK – a move which the company said is “part of our ongoing investment in the UK”.

4. The pharmacovigilance market dynamic

Pharmacovigilance is a science of understanding drug safety through identification, assessment, and prevention of adverse drug reactions.

3. Has Trump’s power over pharma come to an end after Charlottesville?

Pivotal moment for the relationship between Donald Trump and industry, as MSD CEO Kenneth Frazier leads the collapse of the President’s manufacturing committee.

2. UK’s post-Brexit strategy looks to life sciences industry

A new report has been published looking at how the life sciences can form a core part of the UK’s industrial growth.

1. CAR-T treatment is given ‘historic’ first approval by FDA

Novartis has received approval for its CAR-T treatment of paediatric and young adults with a form of acute lymphoblastic leukaemia (ALL). 

Related Content


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso …

Thermo Fisher and Pfizer collaborate on NGS-based cancer tests

Scientific equipment provider Thermo Fisher and US pharmaceutical firm Pfizer have announced a collaboration to …

Latest content